LBA
MRNA icon

Letko, Brosseau & Associates’s Moderna MRNA Stock Holding History

Letko, Brosseau & Associates’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.8M Sell
724,830
-23,985
-3% -$1.24M 0.75% 45
2026
Q1 		$38M Buy
748,815
+22,375
+3% +$1.04M 0.61% 51
2025
Q4 		$21.4M Sell
726,440
-186,950
-20% -$5.08M 0.35% 61
2025
Q3 		$23.6M Sell
913,390
-4,800
-0.5% -$134K 0.41% 59
2025
Q2 		$25.3M Buy
918,190
+21,765
+2% +$573K 0.48% 55
2025
Q1 		$25.4M Sell
896,425
-26,920
-3% -$955K 0.54% 53
2024
Q4 		$38.4M Buy
923,345
+412,200
+81% +$19.7M 0.74% 52
2024
Q3 		$34.2M Buy
511,145
+195,745
+62% +$18M 0.62% 53
2024
Q2 		$37.5M Sell
315,400
-4,650
-1% -$588K 0.71% 50
2024
Q1 		$34.1M Buy
320,050
+620
+0.2% +$62.5K 0.59% 57
2023
Q4 		$31.8M Buy
+319,430
New +$26.9M 0.58% 57

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Letko, Brosseau & Associates's MRNA Position: Q2 2026 in Review

Letko, Brosseau & Associates reduced its Moderna (MRNA) stake by 3.2% in Q2 2026, selling an estimated $1.24M and leaving 724,830 shares worth $50.8M. The position accounts for 0.75% of the portfolio, ranked #45.

Letko, Brosseau & Associates first reported a position in MRNA in Q4 2023 and has held it in 11 quarters since. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Letko, Brosseau & Associates held 724,830 shares of Moderna worth $50.8M as of Q2 2026.
  • Letko, Brosseau & Associates sold 23,985 Moderna shares in Q2 2026, an estimated $1.24M.
  • Moderna made up 0.75% of Letko, Brosseau & Associates's portfolio in Q2 2026, its #45 holding.
  • Letko, Brosseau & Associates first reported a position in Moderna in Q4 2023 and has held it in 11 quarters since.
  • 780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Letko, Brosseau & Associates's 13F filing for Q2 2026, filed 13 Aug 2026.